Wharton S, Serodio K J
Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14, Hamilton, ON, L8L 5G8, Canada,
Curr Cardiol Rep. 2015 May;17(5):35. doi: 10.1007/s11886-015-0590-z.
Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal authorization. Recently, several countries have approved some newer generation weight management medications which may be beneficial to combat obesity. These medications have varying effects on cardiometabolic parameters, both positive and potentially negative. This review will outline the mechanisms of action of these medications and their implications for both diabetes and cardiovascular risks.
自20世纪80年代以来，全球肥胖症患病率几乎翻了一番。肥胖症的治疗方法包括生活方式改变、药物治疗和手术治疗。新型抗肥胖药物已被证明除了能成功实现长期体重维持外，还能有效诱导初始体重管理。从历史上看，体重管理药物一直存在公共安全问题，导致大多数药物被撤出市场或从未获得药物授权。最近，几个国家已批准了一些新一代体重管理药物，这些药物可能有助于对抗肥胖症。这些药物对心脏代谢参数有不同影响，既有积极影响，也有潜在负面影响。本综述将概述这些药物的作用机制及其对糖尿病和心血管风险的影响。
